Chronic Infection and Severe Asthma

Immunology and Allergy Clinics of North America

Volumn 36, Issue 3, 2016, Pages 483-502

  Carr, Tara F ^a   Kraft, Monica ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

Chlamydophila pneumoniae; Chronic infection; Macrolides; Microbiome; Mycoplasma pneumoniae; Severe asthma

Indexed keywords

MACROLIDE; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; ASTHMA; BACTERIAL INFECTION; BACTERIAL VIRULENCE; BLOOD CULTURE; CHLAMYDIA PNEUMONIAE; CHLAMYDIAL PNEUMONIA; CHRONIC DISEASE; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; EXPERIMENTAL MODEL; HUMAN; MICROBIOME; MYCOPLASMA PNEUMONIA; MYCOPLASMA PNEUMONIAE; NONHUMAN; PATHOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; SEROLOGY; STEROID THERAPY; WHEEZING; ANIMAL; COMPLICATION; INFECTION; MICROBIOLOGY; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX;

ANIMALS; ANTI-BACTERIAL AGENTS; ASTHMA; CHLAMYDIAL PNEUMONIA; CHRONIC DISEASE; DISEASE PROGRESSION; HUMANS; INFECTION; MACROLIDES; PNEUMONIA, MYCOPLASMA; SEVERITY OF ILLNESS INDEX;

EID: 84976479928     PISSN: 08898561     EISSN: 15578607     Source Type: Journal    
DOI: 10.1016/j.iac.2016.03.010     Document Type: Review

References (142)

1. 1 Sabato, A.R., Martin, A.J., Marmion, B.P., et al. Mycoplasma pneumoniae: acute illness, antibiotics, and subsequent pulmonary function. Arch Dis Child 59:11 (1984), 1034–1037.
2. 2 Jain, S., Williams, D.J., Arnold, S.R., et al. Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med 372:9 (2015), 835–845.
3. 3 Saraya, T., Kurai, D., Nakagaki, K., et al. Novel aspects on the pathogenesis of Mycoplasma pneumoniae pneumonia and therapeutic implications. Front Microbiol, 5, 2014, 410.
4. 4 Diaz, M.H., Benitez, A.J., Winchell, J.M., Investigations of Mycoplasma pneumoniae infections in the United States: trends in molecular typing and macrolide resistance from 2006 to 2013. J Clin Microbiol 53:1 (2015), 124–130.
5. 5 Waites, K.B., Talkington, D.F., Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev 17:4 (2004), 697–728.
6. 6 Waites, K.B., Balish, M.F., Atkinson, T.P., New insights into the pathogenesis and detection of Mycoplasma pneumoniae infections. Future Microbiol 3:6 (2008), 635–648.
7. 7 Pilo, P., Vilei, E.M., Peterhans, E., et al. A metabolic enzyme as a primary virulence factor of Mycoplasma mycoides subsp. mycoides small colony. J Bacteriol 187:19 (2005), 6824–6831.
8. 8 Hames, C., Halbedel, S., Hoppert, M., et al. Glycerol metabolism is important for cytotoxicity of Mycoplasma pneumoniae. J Bacteriol 191:3 (2009), 747–753.
9. 9 Elkhal, C.K., Kean, K.M., Parsonage, D., et al. Structure and proposed mechanism of l-alpha-glycerophosphate oxidase from Mycoplasma pneumoniae. FEBS J 282:16 (2015), 3030–3042.
10. 10 Chu, H.W., Campbell, J.A., Harbeck, R.J., et al. Effects of inhaled fluticasone on bronchial hyperresponsiveness and airway inflammation in Mycoplasma pneumoniae-infected mice. Chest, 123(Suppl 3), 2003, 427s.
11. 11 Bose, S., Segovia, J.A., Somarajan, S.R., et al. ADP-ribosylation of NLRP3 by Mycoplasma pneumoniae CARDS toxin regulates inflammasome activity. MBio, 5(6), 2014.
12. 12 Kannan, T.R., Baseman, J.B., ADP-ribosylating and vacuolating cytotoxin of Mycoplasma pneumoniae represents unique virulence determinant among bacterial pathogens. Proc Natl Acad Sci U S A 103:17 (2006), 6724–6729.
13. 13 Somarajan, S.R., Al-Asadi, F., Ramasamy, K., et al. Annexin A2 mediates Mycoplasma pneumoniae community-acquired respiratory distress syndrome toxin binding to eukaryotic cells. MBio, 5(4), 2014.
14. 14 Becker, A., Kannan, T.R., Taylor, A.B., et al. Structure of CARDS toxin, a unique ADP-ribosylating and vacuolating cytotoxin from Mycoplasma pneumoniae. Proc Natl Acad Sci U S A 112:16 (2015), 5165–5170.
15. 15 Fang, Y.T., Lin, C.F., Wang, C.Y., et al. Interferon-gamma stimulates p11-dependent surface expression of annexin A2 in lung epithelial cells to enhance phagocytosis. J Cell Physiol 227:6 (2012), 2775–2787.
16. 16 Shimizu, T., Kida, Y., Kuwano, K., Triacylated lipoproteins derived from Mycoplasma pneumoniae activate nuclear factor-kappaB through toll-like receptors 1 and 2. Immunology 121:4 (2007), 473–483.
17. 17 Lee, K.E., Kim, K.W., Hong, J.Y., et al. Modulation of IL-8 boosted by Mycoplasma pneumoniae lysate in human airway epithelial cells. J Clin Immunol 33:6 (2013), 1117–1125.
18. 18 Shimizu, T., Kimura, Y., Kida, Y., et al. Cytadherence of Mycoplasma pneumoniae induces inflammatory responses through autophagy and toll-like receptor 4. Infect Immun 82:7 (2014), 3076–3086.
19. 19 Lai, J.F., Zindl, C.L., Duffy, L.B., et al. Critical Role of Macrophages and Their Activation via MyD88-NFκB Signaling in Lung Innate Immunity to Mycoplasma pneumoniae. PLoS One, 5(12), 2010, e14417.
20. 20 Ledford, J.G., Voelker, D.R., Addison, K.J., et al. Genetic variation in SP-A2 leads to differential binding to Mycoplasma pneumoniae membranes and regulation of host responses. J Immunol 194:12 (2015), 6123–6132.
21. 21 Xu, X., Zhang, D., Lyubynska, N., et al. Mast cells protect mice from Mycoplasma pneumonia. Am J Respir Crit Care Med 173:2 (2006), 219–225.
22. 22 Hsia, B.J., Ledford, J.G., Potts-Kant, E.N., et al. Mast cell TNF receptors regulate responses to Mycoplasma pneumoniae in surfactant protein A (SP-A)-/- mice. J Allergy Clin Immunol 130:1 (2012), 205–214.e202.
23. 23 Medina, J.L., Coalson, J.J., Brooks, E.G., et al. Mycoplasma pneumoniae CARDS toxin induces pulmonary eosinophilic and lymphocytic inflammation. Am J Respir Cell Mol Biol 46:6 (2012), 815–822.
24. 24 Medina, J.L., Coalson, J.J., Brooks, E.G., et al. Mycoplasma pneumoniae CARDS toxin exacerbates ovalbumin-induced asthma-like inflammation in BALB/c mice. PLoS One, 9(7), 2014, e102613.
25. 25 Chu, H.W., Honour, J.M., Rawlinson, C.A., et al. Effects of respiratory Mycoplasma pneumoniae infection on allergen-induced bronchial hyperresponsiveness and lung inflammation in mice. Infect Immun 71:3 (2003), 1520–1526.
26. 26 Martin, R.J., Chu, H.W., Honour, J.M., et al. Airway inflammation and bronchial hyperresponsiveness after Mycoplasma pneumoniae infection in a murine model. Am J Respir Cell Mol Biol 24:5 (2001), 577–582.
27. 27 Zhang, H., Wei, B., Shang, Y.X., et al. Effects of Mycoplasma pneumoniae infection on airway neurokinin-1 receptor expression in BALB/c mice. Genet Mol Res 13:4 (2014), 8320–8328.
28. 28 Hao, Y., Kuang, Z., Jing, J., et al. Mycoplasma pneumoniae modulates STAT3-STAT6/EGFR-FOXA2 signaling to induce overexpression of airway mucins. Infect Immun 82:12 (2014), 5246–5255.
29. 29 Wu, Q., Case, S.R., Minor, M.N., et al. A novel function of MUC18: amplification of lung inflammation during bacterial infection. Am J Pathol 182:3 (2013), 819–827.
30. 30 Chu, H.W., Rino, J.G., Wexler, R.B., et al. Mycoplasma pneumoniae infection increases airway collagen deposition in a murine model of allergic airway inflammation. Am J Physiol Lung Cell Mol Physiol 289:1 (2005), L125–L133.
31. 31 Koh, Y.Y., Park, Y., Lee, H.J., et al. Levels of interleukin-2, interferon-gamma, and interleukin-4 in bronchoalveolar lavage fluid from patients with Mycoplasma pneumonia: implication of tendency toward increased immunoglobulin E production. Pediatrics, 107(3), 2001, E39.
32. 32 Wu, S.H., Chen, X.Q., Kong, X., et al. Characteristics of respiratory syncytial virus-induced bronchiolitis co-infection with Mycoplasma pneumoniae and add-on therapy with montelukast. World J Pediatr 12:1 (2016), 88–95.
33. 33 Guo, L., Liu, F., Lu, M.P., et al. Increased T cell activation in BALF from children with Mycoplasma pneumoniae pneumonia. Pediatr Pulmonol 50:8 (2015), 814–819.
34. 34 Kim, J.H., Cho, T.S., Moon, J.H., et al. Serial Changes in Serum Eosinophil-associated Mediators between Atopic and Non-atopic Children after Mycoplasma pneumoniae pneumonia. Allergy Asthma Immunol Res 6:5 (2014), 428–433.
35. 35 Ye, Q., Xu, X.J., Shao, W.X., et al. Mycoplasma pneumoniae infection in children is a risk factor for developing allergic diseases. ScientificWorldJournal, 2014, 2014, 986527.
36. 36 Wang, L., Chen, Q., Shi, C., et al. Changes of serum TNF-alpha, IL-5 and IgE levels in the patients of mycoplasma pneumonia infection with or without bronchial asthma. Int J Clin Exp Med 8:3 (2015), 3901–3906.
37. 37 Jeong, Y.C., Yeo, M.S., Kim, J.H., et al. Mycoplasma pneumoniae infection affects the serum levels of vascular endothelial growth factor and interleukin-5 in atopic children. Allergy Asthma Immunol Res 4:2 (2012), 92–97.
38. 38 Shin, J.E., Cheon, B.R., Shim, J.W., et al. Increased risk of refractory Mycoplasma pneumoniae pneumonia in children with atopic sensitization and asthma. Korean J Pediatr 57:6 (2014), 271–277.
39. 39 Wang, Y., Zhu, Z., Church, T.D., et al. SHP-1 as a critical regulator of Mycoplasma pneumoniae-induced inflammation in human asthmatic airway epithelial cells. J Immunol 188:7 (2012), 3371–3381.
40. 40 Shao, L., Cong, Z., Li, X., et al. Changes in levels of IL-9, IL-17, IFN-gamma, dendritic cell numbers and TLR expression in peripheral blood in asthmatic children with Mycoplasma pneumoniae infection. Int J Clin Exp Pathol 8:5 (2015), 5263–5272.
41. 41 Ferreira, D.S., Annoni, R., Silva, L.F., et al. Toll-like receptors 2, 3 and 4 and thymic stromal lymphopoietin expression in fatal asthma. Clin Exp Allergy 42:10 (2012), 1459–1471.
42. 42 Sutherland, E.R., Martin, R.J., Asthma and atypical bacterial infection. Chest 132:6 (2007), 1962–1966.
43. 43 Hong, S.J., The role of Mycoplasma pneumoniae infection in asthma. Allergy Asthma Immunol Res 4:2 (2012), 59–61.
44. 44 Darveaux, J.I., Lemanske, R.F. Jr., Infection-related asthma. J Allergy Clin Immunol Pract 2:6 (2014), 658–663.
45. 45 Friedlander, A.L., Albert, R.K., Chronic macrolide therapy in inflammatory airways diseases. Chest 138:5 (2010), 1202–1212.
46. 46 Yano, T., Ichikawa, Y., Komatu, S., et al. Association of Mycoplasma pneumoniae antigen with initial onset of bronchial asthma. Am J Respir Crit Care Med 149:5 (1994), 1348–1353.
47. 47 Esposito, S., Blasi, F., Arosio, C., et al. Importance of acute Mycoplasma pneumoniae and Chlamydia pneumoniae infections in children with wheezing. Eur Respir J 16:6 (2000), 1142–1146.
48. 48 Kim, C.K., Chung, C.Y., Kim, J.S., et al. Late abnormal findings on high-resolution computed tomography after Mycoplasma pneumonia. Pediatrics 105:2 (2000), 372–378.
49. 49 Puolakkainen, M., Innate immunity and vaccines in chlamydial infection with special emphasis on Chlamydia pneumoniae. FEMS Immunol Med Microbiol 55:2 (2009), 167–177.
50. 50 Costa, C.P., Kirschning, C.J., Busch, D., et al. Role of chlamydial heat shock protein 60 in the stimulation of innate immune cells by Chlamydia pneumoniae. Eur J Immunol 32:9 (2002), 2460–2470.
51. 51 Da Costa, C.U., Wantia, N., Kirschning, C.J., et al. Heat shock protein 60 from Chlamydia pneumoniae elicits an unusual set of inflammatory responses via Toll-like receptor 2 and 4 in vivo. Eur J Immunol 34:10 (2004), 2874–2884.
52. 52 Zhou, Z., Wu, Y., Chen, L., et al. Heat shock protein 10 of Chlamydophila pneumoniae induces proinflammatory cytokines through Toll-like receptor (TLR) 2 and TLR4 in human monocytes THP-1. In Vitro Cell Dev Biol Anim 47:8 (2011), 541–549.
53. 53 Ishii, K.J., Koyama, S., Nakagawa, A., et al. Host innate immune receptors and beyond: making sense of microbial infections. Cell Host Microbe 3:6 (2008), 352–363.
54. 54 Kang, Y., Wang, F., Lu, Z., et al. MAPK kinase 3 potentiates Chlamydia HSP60-induced inflammatory response through distinct activation of NF-kappaB. J Immunol 191:1 (2013), 386–394.
55. 55 Ausiello, C.M., Palazzo, R., Spensieri, F., et al. 60-kDa heat shock protein of Chlamydia pneumoniae is a target of T-cell immune response. J Biol Regul Homeost Agents 19:3–4 (2005), 136–140.
56. 56 Ausiello, C.M., Fedele, G., Palazzo, R., et al. 60-kDa heat shock protein of Chlamydia pneumoniae promotes a T helper type 1 immune response through IL-12/IL-23 production in monocyte-derived dendritic cells. Microbes Infect 8:3 (2006), 714–720.
57. 57 Itoh, R., Murakami, I., Chou, B., et al. Chlamydia pneumoniae harness host NLRP3 inflammasome-mediated caspase-1 activation for optimal intracellular growth in murine macrophages. Biochem Biophys Res Commun 452:3 (2014), 689–694.
58. 58 Matsuo, J., Nakamura, S., Takeda, S., et al. Synergistic costimulatory effect of Chlamydia pneumoniae with carbon nanoparticles on NLRP3 inflammasome-mediated interleukin-1beta secretion in macrophages. Infect Immun 83:7 (2015), 2917–2925.
59. 59 Shimada, K., Crother, T.R., Karlin, J., et al. Caspase-1 dependent IL-1beta secretion is critical for host defense in a mouse model of Chlamydia pneumoniae lung infection. PLoS One, 6(6), 2011, e21477.
60. 60 He, X., Mekasha, S., Mavrogiorgos, N., et al. Inflammation and fibrosis during Chlamydia pneumoniae infection is regulated by IL-1 and the NLRP3/ASC inflammasome. J Immunol 184:10 (2010), 5743–5754.
61. 61 Olivares-Zavaleta, N., Carmody, A., Messer, R., et al. Chlamydia pneumoniae inhibits activated human T lymphocyte proliferation by the induction of apoptotic and pyroptotic pathways. J Immunol 186:12 (2011), 7120–7126.
62. 62 Jupelli, M., Shimada, K., Chiba, N., et al. Chlamydia pneumoniae infection in mice induces chronic lung inflammation, iBALT formation, and fibrosis. PLoS One, 8(10), 2013, e77447.
63. 63 Horvat, J.C., Starkey, M.R., Kim, R.Y., et al. Early-life chlamydial lung infection enhances allergic airways disease through age-dependent differences in immunopathology. J Allergy Clin Immunol 125:3 (2010), 617–625 625.e1–6.
64. 64 Asquith, K.L., Horvat, J.C., Kaiko, G.E., et al. Interleukin-13 promotes susceptibility to chlamydial infection of the respiratory and genital tracts. PLoS Pathog, 7(5), 2011, e1001339.
65. 65 Starkey, M.R., Essilfie, A.T., Horvat, J.C., et al. Constitutive production of IL-13 promotes early-life Chlamydia respiratory infection and allergic airway disease. Mucosal Immunol 6:3 (2013), 569–579.
66. 66 Starkey, M.R., Nguyen, D.H., Brown, A.C., et al. PD-L1 Promotes Early-life Chlamydia Respiratory Infection-induced Severe Allergic Airway Disease. Am J Respir Cell Mol Biol 54:4 (2016), 493–503.
67. 67 Dzhindzhikhashvili, M.S., Joks, R., Smith-Norowitz, T., et al. Doxycycline suppresses Chlamydia pneumoniae-mediated increases in ongoing immunoglobulin E and interleukin-4 responses by peripheral blood mononuclear cells of patients with allergic asthma. J Antimicrob Chemother 68:10 (2013), 2363–2368.
68. 68 Horvat, J.C., Starkey, M.R., Kim, R.Y., et al. Chlamydial respiratory infection during allergen sensitization drives neutrophilic allergic airways disease. J Immunol 184:8 (2010), 4159–4169.
69. 69 Essilfie, A.T., Horvat, J.C., Kim, R.Y., et al. Macrolide therapy suppresses key features of experimental steroid-sensitive and steroid-insensitive asthma. Thorax 70:5 (2015), 458–467.
70. 70 Patel, K.K., Vicencio, A.G., Du, Z., et al. Infectious Chlamydia pneumoniae is associated with elevated interleukin-8 and airway neutrophilia in children with refractory asthma. Pediatr Infect Dis J 29:12 (2010), 1093–1098.
71. 71 Morinaga, Y., Yanagihara, K., Miyashita, N., et al. Azithromycin, clarithromycin and telithromycin inhibit MUC5AC induction by Chlamydophila pneumoniae in airway epithelial cells. Pulm Pharmacol Ther 22:6 (2009), 580–586.
72. 72 Park, C.S., Lee, Y.S., Kwon, H.S., et al. Chlamydophila pneumoniae inhibits corticosteroid-induced suppression of metalloproteinase-9 and tissue inhibitor metalloproteinase-1 secretion by human peripheral blood mononuclear cells. J Med Microbiol 61:Pt 5 (2012), 705–711.
73. 73 Park, C.S., Kim, T.B., Moon, K.A., et al. Chlamydophila pneumoniae enhances secretion of VEGF, TGF-beta and TIMP-1 from human bronchial epithelial cells under Th2 dominant microenvironment. Allergy Asthma Immunol Res 2:1 (2010), 41–47.
74. 74 Kim, T.B., Moon, K.A., Lee, K.Y., et al. Chlamydophila pneumoniae triggers release of CCL20 and vascular endothelial growth factor from human bronchial epithelial cells through enhanced intracellular oxidative stress and MAPK activation. J Clin Immunol 29:5 (2009), 629–636.
75. 75 Dutow, P., Lingner, S., Laudeley, R., et al. Severity of allergic airway disease due to house dust mite allergen is not increased after clinical recovery of lung infection with Chlamydia pneumoniae in mice. Infect Immun 81:9 (2013), 3366–3374.
76. 76 Crother, T.R., Schroder, N.W., Karlin, J., et al. Chlamydia pneumoniae infection induced allergic airway sensitization is controlled by regulatory T-cells and plasmacytoid dendritic cells. PLoS One, 6(6), 2011, e20784.
77. 77 Chiba, N., Shimada, K., Chen, S., et al. Mast cells play an important role in Chlamydia pneumoniae lung infection by facilitating immune cell recruitment into the airway. J Immunol 194:8 (2015), 3840–3851.
78. 78 Zaitsu, M., The development of asthma in wheezing infants with Chlamydia pneumoniae infection. J Asthma 44:7 (2007), 565–568.
79. 79 Hahn, D.L., Dodge, R.W., Golubjatnikov, R., Association of Chlamydia pneumoniae (strain TWAR) infection with wheezing, asthmatic bronchitis, and adult-onset asthma. JAMA 266:2 (1991), 225–230.
80. 80 Cunningham, A.F., Johnston, S.L., Julious, S.A., et al. Chronic Chlamydia pneumoniae infection and asthma exacerbations in children. Eur Respir J 11:2 (1998), 345–349.
81. 81 Biscardi, S., Lorrot, M., Marc, E., et al. Mycoplasma pneumoniae and asthma in children. Clin Infect Dis 38:10 (2004), 1341–1346.
82. 82 Hahn, D.L., Anttila, T., Saikku, P., Association of Chlamydia pneumoniae IgA antibodies with recently symptomatic asthma. Epidemiol Infect 117:3 (1996), 513–517.
83. 83 Hahn, D.L., Chlamydia pneumoniae antibodies and adult-onset asthma. J Allergy Clin Immunol, 106, 2000, 404.
84. 84 Miyatake, H., Taki, F., Taniguchi, H., et al. Erythromycin reduces the severity of bronchial hyperresponsiveness in asthma. Chest 99:3 (1991), 670–673.
85. 85 Kostadima, E., Tsiodras, S., Alexopoulos, E.I., et al. Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma. Eur Respir J 23:5 (2004), 714–717.
86. 86 Hahn, D.L., Grasmick, M., Hetzel, S., et al. Azithromycin for bronchial asthma in adults: an effectiveness trial. J Am Board Fam Med 25:4 (2012), 442–459.
87. 87 Hahn, D.L., Plane, M.B., Mahdi, O.S., et al. Secondary outcomes of a pilot randomized trial of azithromycin treatment for asthma. PLoS Clin Trials, 1(2), 2006, e11.
88. 88 Simpson, J.L., Powell, H., Boyle, M.J., et al. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med 177:2 (2008), 148–155.
89. 89 Shoji, T., Yoshida, S., Sakamoto, H., et al. Anti-inflammatory effect of roxithromycin in patients with aspirin-intolerant asthma. Clin Exp Allergy 29:7 (1999), 950–956.
90. 90 Brusselle, G.G., Vanderstichele, C., Jordens, P., et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax 68:4 (2013), 322–329.
91. 91 Itkin, I.H., Menzel, M.L., The use of macrolide antibiotic substances in the treatment of asthma. J Allergy 45:3 (1970), 146–162.
92. 92 Zeiger, R.S., Schatz, M., Sperling, W., et al. Efficacy of troleandomycin in outpatients with severe, corticosteroid-dependent asthma. J Allergy Clin Immunol 66:6 (1980), 438–446.
93. 93 Siracusa, A., Brugnami, G., Fiordi, T., et al. Troleandomycin in the treatment of difficult asthma. J Allergy Clin Immunol 92:5 (1993), 677–682.
94. 94 Kamada, A.K., Hill, M.R., Iklé, D.N., et al. Efficacy and safety of low-dose troleandomycin therapy in children with severe, steroid-requiring asthma. J Allergy Clin Immunol 91:4 (1993), 873–882.
95. 95 Nelson, H.S., Hamilos, D.L., Corsello, P.R., et al. A double-blind study of troleandomycin and methylprednisolone in asthmatic subjects who require daily corticosteroids. Am Rev Respir Dis 147:2 (1993), 398–404.
96. 96 Garey, K.W., Rubinstein, I., Gotfried, M.H., et al. Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma. Chest 118:6 (2000), 1826–1827.
97. 97 Szefler, S.J., Rose, J.Q., Ellis, E.F., et al. The effect of troleandomycin on methylprednisolone elimination. J Allergy Clin Immunol 66:6 (1980), 447–451.
98. 98 Strunk, R.C., Bacharier, L.B., Phillips, B.R., et al. Azithromycin or montelukast as inhaled corticosteroid-sparing agents in moderate-to-severe childhood asthma study. J Allergy Clin Immunol 122:6 (2008), 1138–1144.e4.
99. 99 Kew, K.M., Undela, K., Kotortsi, I., et al. Macrolides for chronic asthma. Cochrane Database Syst Rev(9), 2015 CD002997.
100. 100 Hansel, T.T., Johnston, S.L., Openshaw, P.J., Microbes and mucosal immune responses in asthma. Lancet 381:9869 (2013), 861–873.
101. 101 Huang, Y.J., The respiratory microbiome and innate immunity in asthma. Curr Opin Pulm Med 21:1 (2015), 27–32.
102. 102 Gollwitzer, E.S., Saglani, S., Trompette, A., et al. Lung microbiota promotes tolerance to allergens in neonates via PD-L1. Nat Med 20:6 (2014), 642–647.
103. 103 Marsland, B.J., Gollwitzer, E.S., Host-microorganism interactions in lung diseases. Nat Rev Immunol 14:12 (2014), 827–835.
104. 104 Fujimura, K.E., Slusher, N.A., Cabana, M.D., et al. Role of the gut microbiota in defining human health. Expert Rev Anti Infect Ther 8:4 (2010), 435–454.
105. 105 Brooks, C., Pearce, N., Douwes, J., The hygiene hypothesis in allergy and asthma: an update. Curr Opin Allergy Clin Immunol 13:1 (2013), 70–77.
106. 106 Lynch, S.V., Wood, R.A., Boushey, H., et al. Effects of early-life exposure to allergens and bacteria on recurrent wheeze and atopy in urban children. J Allergy Clin Immunol 134:3 (2014), 593–601.e12.
107. 107 McCoy, K.D., Koller, Y., New developments providing mechanistic insight into the impact of the microbiota on allergic disease. Clin Immunol 159:2 (2015), 170–176.
108. 108 Bisgaard, H., Li, N., Bonnelykke, K., et al. Reduced diversity of the intestinal microbiota during infancy is associated with increased risk of allergic disease at school age. J Allergy Clin Immunol 128:3 (2011), 646–652.e1-5.
109. 109 Fujimura, K.E., Lynch, S.V., Microbiota in allergy and asthma and the emerging relationship with the gut microbiome. Cell Host Microbe 17:5 (2015), 592–602.
110. 110 Trompette, A., Gollwitzer, E.S., Yadava, K., et al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nat Med 20:2 (2014), 159–166.
111. 111 Park, H., Shin, J.W., Park, S.G., et al. Microbial communities in the upper respiratory tract of patients with asthma and chronic obstructive pulmonary disease. PLoS One, 9(10), 2014, e109710.
112. 112 Marri, P.R., Stern, D.A., Wright, A.L., et al. Asthma-associated differences in microbial composition of induced sputum. J Allergy Clin Immunol 131:2 (2013), 346–352.e1-3.
113. 113 Huang, Y.J., Nelson, C.E., Brodie, E.L., et al. Airway microbiota and bronchial hyperresponsiveness in patients with suboptimally controlled asthma. J Allergy Clin Immunol 127:2 (2011), 372–381.e1-3.
114. 114 Huang, Y.J., Nariya, S., Harris, J.M., et al. The airway microbiome in patients with severe asthma: associations with disease features and severity. J Allergy Clin Immunol 136:4 (2015), 874–884.
115. 115 Green, B.J., Wiriyachaiporn, S., Grainge, C., et al. Potentially pathogenic airway bacteria and neutrophilic inflammation in treatment resistant severe asthma. PLoS One, 9(6), 2014, e100645.
116. 116 Goleva, E., Jackson, L.P., Harris, J.K., et al. The effects of airway microbiome on corticosteroid responsiveness in asthma. Am J Respir Crit Care Med 188:10 (2013), 1193–1201.
117. 117 Slater, M., Rivett, D.W., Williams, L., et al. The impact of azithromycin therapy on the airway microbiota in asthma. Thorax 69 (2014), 673–674.
118. 118 Huang, Y.J., Lynch, S.V., The emerging relationship between the airway microbiota and chronic respiratory disease: clinical implications. Expert Rev Respir Med 5:6 (2011), 809–821.
119. 119 Huang, Y.J., Boushey, H.A., The microbiome and asthma. Ann Am Thorac Soc 11:Suppl 1 (2014), S48–S51.
120. 120 Huang, Y.J., Asthma microbiome studies and the potential for new therapeutic strategies. Curr Allergy Asthma Rep 13:5 (2013), 453–461.
121. 121 Smith-Norowitz, T.A., Silverberg, J.I., Kusonruksa, M., et al. Asthmatic children have increased specific anti-Mycoplasma pneumoniae IgM but not IgG or IgE-values independent of history of respiratory tract infection. Pediatr Infect Dis J 32:6 (2013), 599–603.
122. 122 Bebear, C., Raherison, C., Nacka, F., et al. Comparison of Mycoplasma pneumoniae Infections in asthmatic children versus asthmatic adults. Pediatr Infect Dis J 33:3 (2014), e71–e75.
123. 123 Fonseca-Aten, M., Okada, P.J., Bowlware, K.L., et al. Effect of clarithromycin on cytokines and chemokines in children with an acute exacerbation of recurrent wheezing: a double-blind, randomized, placebo-controlled trial. Ann Allergy Asthma Immunol 97:4 (2006), 457–463.
124. 124 Wood, P.R., Hill, V.L., Burks, M.L., et al. Mycoplasma pneumoniae in children with acute and refractory asthma. Ann Allergy Asthma Immunol 110:5 (2013), 328–334.e1.
125. 125 Kraft, M., Cassell, G.H., Henson, J.E., et al. Detection of Mycoplasma pneumoniae in the airways of adults with chronic asthma. Am J Respir Crit Care Med 158:3 (1998), 998–1001.
126. 126 Martin, R.J., Kraft, M., Chu, H.W., et al. A link between chronic asthma and chronic infection. J Allergy Clin Immunol 107:4 (2001), 595–601.
127. 127 Lieberman, D., Lieberman, D., Printz, S., et al. Atypical Pathogen Infection in Adults with Acute Exacerbation of Bronchial Asthma. Am J Respir Crit Care Med 167:3 (2003), 406–410.
128. 128 Peters, J., Singh, H., Brooks, E.G., et al. Persistence of community-acquired respiratory distress syndrome toxin-producing Mycoplasma pneumoniae in refractory asthma. Chest 140:2 (2011), 401–407.
129. 129 Awasthi, S., Yadav, K.K., Agarwal, J., Chlamydia pneumoniae infection associated with uncontrolled asthma: a hospital based cross sectional study. Indian J Pediatr 79:10 (2012), 1318–1322.
130. 130 Biscione, G.L., Corne, J., Chauhan, A.J., et al. Increased frequency of detection of Chlamydophila pneumoniae in asthma. Eur Respir J 24:5 (2004), 745–749.
131. 131 Miyashita, N., Kubota, Y., Nakajima, M., et al. Chlamydia pneumoniae and exacerbations of asthma in adults. Ann Allergy Asthma Immunol 80:5 (1998), 405–409.
132. 132 Allegra, L., Blasi, F., Centanni, S., et al. Acute exacerbations of asthma in adults: role of Chlamydia pneumoniae infection. Eur Respir J 7:12 (1994), 2165–2168.
133. 133 Black, P.N., Scicchitano, R., Jenkins, C.R., et al. Serological evidence of infection with Chlamydia pneumoniae is related to the severity of asthma. Eur Respir J 15:2 (2000), 254–259.
134. 134 Huittinen, T., Hahn, D., Anttila, T., et al. Host immune response to Chlamydia pneumoniae heat shock protein 60 is associated with asthma. Eur Respir J 17:6 (2001), 1078–1082.
135. 135 Hahn, D.L., Peeling, R.W., Airflow limitation, asthma, and Chlamydia pneumoniae-specific heat shock protein 60. Ann Allergy Asthma Immunol 101:6 (2008), 614–618.
136. 136 Pasternack, R., Huhtala, H., Karjalainen, J., Chlamydophila (Chlamydia) pneumoniae serology and asthma in adults: a longitudinal analysis. J Allergy Clin Immunol 116:5 (2005), 1123–1128.
137. 137 Kraft, M., Cassell, G.H., Pak, J., et al. Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: effect of clarithromycin. Chest 121:6 (2002), 1782–1788.
138. 138 Black, P.N., Blasi, F., Jenkins, C.R., et al. Trial of roxithromycin in subjects with asthma and serological evidence of infection with Chlamydia pneumoniae. Am J Respir Crit Care Med 164:4 (2001), 536–541.
139. 139 Hahn, D.L., Treatment of Chlamydia pneumoniae infection in adult asthma: a before-after trial. J Fam Pract 41:4 (1995), 345–351.
140. 140 Sutherland, E.R., King, T.S., Icitovic, N., et al. A trial of clarithromycin for the treatment of suboptimally controlled asthma. J Allergy Clin Immunol 126:4 (2010), 747–753.
141. 141 Emre, U., Roblin, P.M., Gelling, M., et al. The association of Chlamydia pneumoniae infection and reactive airway disease in children. Arch Pediatr Adolesc Med 148:7 (1994), 727–732.
142. 142 Johnston, S.L., Blasi, F., Black, P.N., et al. The effect of telithromycin in acute exacerbations of asthma. N Engl J Med 354:15 (2006), 1589–1600.